# Endocrinologic and Metabolic Drugs Advisory Committee Hilton Hotel, Washington DC-Silver Spring Silver Spring, Maryland April 1, 2009

### **Meeting Roster**

# ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

### Kenneth D. Burman, M.D.

(Chair) Chief, Endocrine Section Washington Hospital Center Washington, District of Columbia

# Katherine M. Flegal, Ph.D.

Senior Research Scientist Distinguished Consultant National Center for Health Statistics Centers for Disease Control and Prevention Hyattsville, Maryland

### Michael A. Proschan, Ph.D.

Mathematical Statistician Biostatistics Research Branch National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) Bethesda, Maryland

# Eric I. Felner, M.D.

Emory University School of Medicine Department of Pediatrics Division of Endocrinology Atlanta, Georgia

### Jessica W. Henderson, Ph.D.

Associate Professor Division of Health and Physical Education Western Oregon University Monmouth, Oregon

# ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS, INDUSTRY REPRESENTATIVE (Non-Voting)

### Enrico P. Veltri, MD

Group Vice President Global Clinical Development Cardiovascular and Metabolic Diseases Schering-Plough Research Institute Kenilworth, New Jersey

# DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBER (Voting)

# Timothy S. Lesar, Pharm.D.

Director of Pharmacy Albany Medical Center Albany, New York

# Endocrinologic and Metabolic Drugs Advisory Committee Hilton Hotel, Washington DC-Silver Spring Silver Spring, Maryland April 1, 2009

# Meeting Roster

# CENTER FOR DRUG EVALUATION AND RESEARCH TEMPORARY VOTING MEMBERS (Voting)

### Lynne L. Levitsky, M.D.

Chief, Pediatric Endocrine Unit Massachusetts General Hospital Boston, Massachusetts

# John R. Teerlink, M.D.

Associate Professor of Medicine, UCSF Director, Heart Failure Clinic, SFVAMC Director, Clinical Echocardiography, SFVAMC San Francisco VA Medical Center San Francisco, California

# Peter J. Savage, M.D.

Senior Advisor to the Director Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD), NIDDK National Institutes of Health (NIH) Bethesda, Maryland

# FDA PARTICIPANTS (Non-Voting)

### John K. Jenkins, M.D.

Director Office of New Drugs Center for Drug Evaluation and Research (CDER) Food and Drug Administration (FDA)

# Mary H. Parks, M.D.

Director Division of Metabolism and Endocrinology Products CDER, FDA

# Naomi Lowy, M.D.

Clinical Reviewer Division of Metabolism and Endocrinology Products CDER, FDA

#### **Rebecca W. Killion**

Patient Representative Bowie, Maryland

#### Kathleen L. Wyne, M.D., Ph.D.

Director of Clinical Research, Diabetes Research Center The Methodist Hospital Research Institute Assistant Professor, Department of Medicine Weill Cornell Medical College The Methodist Hospital Houston, Texas

### Marvin A. Konstam, M.D.

Chief Physician Executive, The Cardiovascular Center Tufts Medical Center Professor of Medicine Tufts University School of Medicine

#### Curtis Rosebraugh, M.D., M.P.H. Director

Office of Drug Evaluation II CDER, FDA

### Hylton Joffe, M.D. M.M.Sc

Diabetes Clinical Team Leader Division of Metabolism and Endocrinology Products CDER, FDA